Radiodermatitis Market Analysis By Product (Topical, Corticosteroids, Hydrophilic Creams, Antibiotics, Dressings, Hydrogel & Hydrocolloid, No Sting Barrier Film, Silicone Coated), By Distribution Channel, And Segment Forecasts, 2014 - 2025

The global radiodermatitis market is expected to reach USD 442.1 million by 2025, according to a new report by Grand View Research, Inc. The global radiodermatitis market is expected to grow at an unprecedented rate owing to the growing prevalence of cancer patients undergoing radiation therapy. The demand for radiodermatitis treatment is also accentuated by unmet medical needs of consumers in emerging as well as developed regions. Increasing focus of government healthcare organizations for promoting awareness about available treatment products for radiodermatitisis predicted to present the market with high potential growth opportunities.
In addition, increasing R&D activities in the area of life sciences is presumed to be one of the significant factors contributing toward growth of this market. For instance, in December 2016, Molnlycke Health Care AB entered into a licensing agreement with a Texas-based R&D company Rochal Industries. This agreement was carried out to reinforce its position as a prevention solutions firm. In addition, they have signed a joint agreement to enhance their R&D capabilities and commercialize new patented technological platforms.Other factors such as escalating number of product launches with respect to radiodermatitis treatment and increasing demand for these products are expected to boost the overall market growth.
Further key findings from the report suggest:
‧ Topical products captured the largest share in the product segment in 2016. The dominant share is attributable to ease in availability, greater convenience, and superiority over oral products
‧ Topical products are also anticipated to grow at an exponential rate owing to their availability in various formulations such as creams, gels, and ointments according to the requirement of the patient
‧ In 2016, retail pharmacy accounted for the substantial share of the distribution channel segment as a consequence of ease in availability and high convenience associated with it.
‧ Asia Pacific held the largest share of the radiodermatitis market owing to presence of a large cancer patient base present across this region
‧ North America held the secondlargest share owing to extensive R&D activities that have fueled high potential growth opportunities
‧ In addition, availability of therapeutically advanced products across North America is one of the major factors contributing toward itshighshare
‧ The competition is marked by major players undertaking strategies such as product launches, distribution agreements, and strategic collaborations that haveled to significant growth in their respective market share

Table of Contents
Chapter 1 Research Methodology & Scope
1.1 Region Wise Market Calculation
1.1.1 Region-wise market: Base estimates
1.1.2 Global market: CAGR calculation
1.2 Region-Based Segment Share Calculation
1.3 List of Secondary Sources
Chapter 2 Executive Summary
Chapter 3 Radiodermatitis Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.3 Market Restraint Analysis
3.4 Penetration & Growth Prospect Mapping
3.5 Radiodermatitis Market - SWOT Analysis, By Factor (Political & legal, economic and technological)
3.6 Industry Analysis - Porter’s
Chapter 4 Radiodermatitis Market: Product Estimates & Trend Analysis
4.1 Radiodermatitis Market: Product Movement Analysis
4.2 Topical
4.2.1 Topical market estimates and forecasts, 2014 - 2025 (USD Million)
4.2.2 Corticosteroids
4.2.2.1 Corticosteroids market estimates and forecasts, 2014 - 2025 (USD Million)
4.2.3 Hydrophilic creams
4.2.3.1 Hydrophilic creams market estimates and forecasts, 2014 - 2025 (USD Million)
4.2.4 Antibiotics
4.2.4.1 Antibiotics market estimates and forecasts, 2014 - 2025 (USD Million)
4.2.5 Others
4.2.5.1 Others market estimates and forecasts, 2014 - 2025 (USD Million)
4.3 Oral
4.3.1 Oral market estimates and forecasts, 2014 - 2025 (USD Million)
4.4 Dressings
4.4.1 Dressings market estimates and forecasts, 2014 - 2025 (USD Million)
4.4.2 Hydrogel & hydrocolloid dressing
4.4.2.1 Hydrogel & hydrocolloid dressing market estimates and forecasts, 2014 - 2025 (USD Million)
4.4.3 No sting barrier film
4.4.3.1 No sting barrier film market estimates and forecasts, 2014 - 2025 (USD Million)
4.4.4 Honey impregnated gauze
4.4.4.1 Honey impregnated gauze market estimates and forecasts, 2014 - 2025 (USD Million)
4.4.5 Silicone coated dressings
4.4.5.1 Silicone coated dressings market estimates and forecasts, 2014 - 2025 (USD Million)
4.4.6 Others
4.4.6.1 Others market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 5 Radiodermatitis Market: Distribution Channel Estimates & Trend Analysis
5.1 Radiodermatitis Market: Distribution Channel Movement Analysis
5.2 Hospital Pharmacy
5.2.1 Hospital pharmacy market estimates and forecasts, 2014 - 2025 (USD Million)
5.3 Retail Pharmacy
5.3.1 Retail pharmacy estimates and forecasts, 2014 - 2025 (USD Million)
5.4 Online Pharmacies
5.4.1 Online pharmacies market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 6 Radiodermatitis Market: Regional Estimates & Trend Analysis, by Product & Distribution Channel
6.1 Radiodermatitis Market Shares By Region, 2016 & 2025
6.2 North America
6.2.1 North America radiodermatitis market, by product, 2014 - 2025 (USD Million)
6.2.2 North America radiodermatitis market, by distribution channel, 2014 - 2025 (USD Million)
6.2.3 U.S.
6.2.3.1 U.S. radiodermatitis market, by product, 2014 - 2025 (USD Million)
6.2.3.2 U.S. radiodermatitis market, by distribution channel, 2014 - 2025 (USD Million)
6.2.4 Canada
6.2.4.1 Canada radiodermatitis market, by product, 2014 - 2025 (USD Million)
6.2.4.2 Canada radiodermatitis market, by distribution channel, 2014 - 2025 (USD Million)
6.3 Europe
6.3.1 Europe radiodermatitis market, by product, 2014 - 2025 (USD Million)
6.3.2 Europe radiodermatitis market, by distribution channel, 2014 - 2025 (USD Million)
6.3.3 UK
6.3.3.1 UK radiodermatitis market estimates and forecasts, 2014 - 2025(USD Million)
6.3.3.2 UK radiodermatitis market, by product, 2014 - 2025 (USD Million)
6.3.3.3 UK radiodermatitis market, by distribution channel, 2014 - 2025 (USD Million)
6.3.4 Germany
6.3.4.1 Germany radiodermatitis market, by product, 2014 - 2025 (USD Million)
6.3.4.2 Germany radiodermatitis market, by distribution channel, 2014 - 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific radiodermatitis market, by product, 2014 - 2025 (USD Million)
6.4.2 Asia Pacific radiodermatitis market, by distribution channel, 2014 - 2025 (USD Million)
6.4.3 Japan
6.4.3.1 Japan radiodermatitis market, by product, 2014 - 2025 (USD Million)
6.4.3.2 Japan radiodermatitis market, by distribution channel, 2014 - 2025 (USD Million)
6.4.4 China
6.4.4.1 China radiodermatitis market, by product, 2014 - 2025 (USD Million)
6.4.4.2 China radiodermatitis market, by distribution channel, 2014 - 2025 (USD Million)
6.4.5 India
6.4.5.1 India radiodermatitis market, by product, 2014 - 2025 (USD Million)
6.4.5.2 India radiodermatitis market, by distribution channel, 2014 - 2025 (USD Million)
6.5 Latin America
6.5.1 Latin America radiodermatitis market, by product, 2014 - 2025 (USD Million)
6.5.2 Latin America radiodermatitis market, by distribution channel, 2014 - 2025 (USD Million)
6.5.3 Brazil
6.5.3.1 Brazil radiodermatitis market, by product, 2014 - 2025 (USD Million)
6.5.3.2 Brazil radiodermatitis market, by distribution channel, 2014 - 2025 (USD Million)
6.5.4 Mexico
6.5.4.1 Mexico radiodermatitis market, by product, 2014 - 2025 (USD Million)
6.5.4.2 Mexico radiodermatitis market, by distribution channel, 2014 - 2025 (USD Million)
6.6 MEA
6.6.1 MEA radiodermatitis market, by product, 2014 - 2025 (USD Million)
6.6.2 MEA radiodermatitis market, by distribution channel, 2014 - 2025 (USD Million)
6.6.3 South Africa
6.6.3.1 South Africa radiodermatitis market, by product, 2014 - 2025 (USD Million)
6.6.3.2 South Africa radiodermatitis market, by distribution channel, 2014 - 2025 (USD Million)
Chapter 7 Competitive Landscape
7.1 Strategy Framework
7.2 Market Participation Categorization
7.3 Company Profiles
7.3.1 Stratpharma AG
7.3.1.1 Company overview
7.3.1.2 Financial performance
7.3.1.3 Product benchmarking
7.3.1.4 Strategic initiatives
7.3.2 Smith & Nephew
7.3.2.1 Company Overview
7.3.2.2 Financial Performance
7.3.2.3 Product Benchmarking
7.3.2.4 Strategic initiatives
7.3.3 Molnlycke Health Care AB
7.3.3.1 Company Overview
7.3.3.2 Financial Performance
7.3.3.3 Product Benchmarking
7.3.3.4 Strategic initiatives
7.3.4 Derma Sciences Inc.
7.3.4.1 Company overview
7.3.4.2 Financial Performance
7.3.4.3 Product Benchmarking
7.3.4.4 Strategic initiatives
7.3.5 ConvaTec Inc.
7.3.5.1 Company overview
7.3.5.2 Financial performance
7.3.5.3 Product benchmarking
7.3.4.4 Strategic initiatives
7.3.6 BMG Pharma S.R.L.
7.3.6.1 Company overview
7.3.6.2 Financial performance
7.3.6.3 Product benchmarking
7.3.6.4 Strategic initiatives
7.3.7 Acelity
7.3.7.1 Company overview
7.3.7.2 Financial performance
7.3.7.3 Product benchmarking
7.3.7.4 Strategic initiatives
7.3.8 3M
7.3.8.1 Company Overview
7.3.8.2 Financial Performance
7.3.8.3 Product Benchmarking
7.3.9 Alliqua BioMedical
7.3.9.1 Company overview
7.3.9.2 Financial performance
7.3.9.3 Product benchmarking
7.3.4.4 Strategic initiatives